Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  403 results for ""Lutetium""

Your Filters

Subject : octreotide
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Lutetium oxodotreotide ( 177 Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland.

Subjects: Cost-Benefit Analysis*; Intestinal Neoplasms/Intestinal Neoplasms/Intestinal Neoplasms/*economics ; Intestinal Neoplasms/Intestinal Neoplasms/Intestinal Neoplasms/*radiotherapy Gastro-enteropancreatic neuroendocrine tumor

  • Source: BMC cancer [BMC Cancer] 2021 Jan 05; Vol. 21 (1), pp. 10. Date of Electronic Publication: 2021 Jan 05.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent 177 Lu-DOTATOC therapy.

  • Authors : Goetz TI; Department of Nuclear Medicine, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany.; Pattern Recognition Lab, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany.

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacokinetics ; Lutetium/Lutetium/Lutetium/*pharmacokinetics ; Neuroendocrine Tumors/Neuroendocrine Tumors/Neuroendocrine Tumors/*radiotherapy

  • Source: Annals of nuclear medicine [Ann Nucl Med] 2020 Apr; Vol. 34 (4), pp. 244-253. Date of Electronic Publication: 2020 Feb 29.Publisher: Springer Japan Country of Publication: Japan NLM ID: 8913398 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition.

  • Authors : Hofving T; Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Cancer Center, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.; Sandblom V

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; HSP90 Heat-Shock Proteins/HSP90 Heat-Shock Proteins/HSP90 Heat-Shock Proteins/*antagonists & inhibitors ; Lutetium/Lutetium/Lutetium/*therapeutic use

  • Source: Endocrine-related cancer [Endocr Relat Cancer] 2019 Apr 01; Vol. 26 (4), pp. 437-449. Date of Electronic Publication: 2019 Feb 01.Publisher: BioScientifica Country of Publication: England NLM ID: 9436481 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors.

  • Authors : Zandee WT; Department of Internal Medicine, Sector of Endocrinology, Erasmus Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands.; Brabander T

Subjects: Coordination Complexes/Coordination Complexes/Coordination Complexes/*administration & dosage ; Lutetium/Lutetium/Lutetium/*administration & dosage ; Neuroendocrine Tumors/Neuroendocrine Tumors/Neuroendocrine Tumors/*radiotherapy

  • Source: The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2019 Apr 01; Vol. 104 (4), pp. 1336-1344.Publisher: Oxford University Press Country of Publication: United States NLM ID: 0375362 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

High-Specific-Activity- 131 I-MIBG versus 177 Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma.

  • Authors : Jha A; Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, Maryland.; Taïeb D

Subjects: 3-Iodobenzylguanidine/3-Iodobenzylguanidine/3-Iodobenzylguanidine/*therapeutic use ; Adrenal Gland Neoplasms/Adrenal Gland Neoplasms/Adrenal Gland Neoplasms/*radiotherapy ; Adrenal Gland Neoplasms/Adrenal Gland Neoplasms/Adrenal Gland Neoplasms/*secondary

  • Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jun 01; Vol. 27 (11), pp. 2989-2995. Date of Electronic Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Neuroblastoma xenograft models demonstrate the therapeutic potential of 177 Lu-octreotate.

  • Authors : Romiani A; Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Center for Cancer Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. .; Department of Medical Physics, Sahlgrenska University Hospital, SE-41345, Gothenburg, Sweden. .

Subjects: Lutetium/Lutetium/Lutetium/*therapeutic use ; Neuroblastoma/Neuroblastoma/Neuroblastoma/*radiotherapy ; Octreotide/Octreotide/Octreotide/*analogs & derivatives

  • Source: BMC cancer [BMC Cancer] 2021 Aug 25; Vol. 21 (1), pp. 950. Date of Electronic Publication: 2021 Aug 25.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Enhancing the anti-tumour activity of 177 Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP.

  • Authors : Cullinane C; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. .; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia. .

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacology ; Lutetium/Lutetium/Lutetium/*physiology ; Neuroendocrine Tumors/Neuroendocrine Tumors/Neuroendocrine Tumors/*drug therapy

  • Source: Scientific reports [Sci Rep] 2020 Jun 23; Vol. 10 (1), pp. 10196. Date of Electronic Publication: 2020 Jun 23.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Complete remission of inoperable hepatic and bone metastases due to neuroendocrine pancreatic tumour 3 years after peptide receptor radionucleotide therapy.

  • Authors : Soeiro P; Nuclear Medicine, Centro Hospitalar e Universitário de Coimbra EPE, Coimbra, Portugal .; Martins H

Subjects: Antineoplastic Agents, Hormonal/Antineoplastic Agents, Hormonal/Antineoplastic Agents, Hormonal/*therapeutic use ; Lutetium/Lutetium/Lutetium/*therapeutic use ; Neuroendocrine Tumors/Neuroendocrine Tumors/Neuroendocrine Tumors/*therapy

  • Source: BMJ case reports [BMJ Case Rep] 2020 Mar 31; Vol. 13 (3). Date of Electronic Publication: 2020 Mar 31.Publisher: BMJ Pub. Group Country of Publication: England NLM ID: 101526291 Publication Model: Electronic Cited Medium: Internet ISSN: 1757-790X

Record details

Read More Add to Saved list
×
Academic Journal

177 Lu-DOTATATE treatment in neuroendocrine tumours. A preliminary study.

  • Authors : Hervás I; Servicio de Medicina Nuclear, Hospital Universitario La Fe, Valencia, España. Electronic address: .; Bello P

Subjects: Lutetium/Lutetium/Lutetium/*therapeutic use ; Neuroendocrine Tumors/Neuroendocrine Tumors/Neuroendocrine Tumors/*radiotherapy ; Octreotide/Octreotide/Octreotide/*analogs & derivatives

  • Source: Revista espanola de medicina nuclear e imagen molecular [Rev Esp Med Nucl Imagen Mol] 2017 Mar - Apr; Vol. 36 (2), pp. 91-98. Date of Electronic Publication: 2016 Nov 23.Publisher: Elsevier España Country of Publication: Spain NLM ID: 101585329 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Editorial & Opinion

Treatment with 177 Lu-DOTATATE: Past, present and future.

  • Authors : Estorch M; Servicio de Medicina Nuclear, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, España; Grupo de Trabajo de Endocrinología de la SEMNIM. Electronic address: .

Subjects: Molecular Targeted Therapy*; Lutetium/Lutetium/Lutetium/*therapeutic use ; Neoplasm Proteins/Neoplasm Proteins/Neoplasm Proteins/*metabolism

  • Source: Revista espanola de medicina nuclear e imagen molecular [Rev Esp Med Nucl Imagen Mol] 2017 Mar - Apr; Vol. 36 (2), pp. 69-71.Publisher: Elsevier España Country of Publication: Spain NLM ID: 101585329 Publication Model: Print Cited Medium: Internet ISSN: 2253-8070

Record details

Read More Add to Saved list
×
  • 1-10 of  403 results for ""Lutetium""